TNFSF13B and pemphigus: Ianalumab is an experimental mAb that binds to BLyS, A phase 2 clinical trial was conducted to determine the doses, benefits, and safety of ianalumab in patients with PV, showing a 73% decrease in mean PDAI score at week 12 in seven patients with pemphigus compared with placebo-treated controls.121